Literature DB >> 20567526

Advances in IBD: Current Developments in the Treatment of Inflammatory Bowel Diseases.

.   

Abstract

Year:  2009        PMID： 20567526      PMCID： PMC2886386     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  7 in total

1.  A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

Authors:  Marla C Dubinsky; Eileen Reyes; Joshua Ofman; Chiun-Fang Chiou; Sally Wade; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2005-10       Impact factor: 10.864

2.  6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

Authors:  Marla C Dubinsky; Huiying Yang; Philip V Hassard; Ernest G Seidman; Lori Y Kam; Maria T Abreu; Stephan R Targan; Eric A Vasiliauskas
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

3.  Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.

Authors:  Miles P Sparrow; Scott A Hande; Sonia Friedman; Dingcai Cao; Stephen B Hanauer
Journal:  Clin Gastroenterol Hepatol       Date:  2007-02       Impact factor: 11.382

4.  Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis.

Authors:  Mark T Osterman; Rabi Kundu; Gary R Lichtenstein; James D Lewis
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

5.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

Authors:  R M Weinshilboum; S L Sladek
Journal:  Am J Hum Genet       Date:  1980-09       Impact factor: 11.025

6.  Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.

Authors:  J Winter; A Walker; D Shapiro; D Gaffney; R J Spooner; P R Mills
Journal:  Aliment Pharmacol Ther       Date:  2004-09-15       Impact factor: 8.171

7.  6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial.

Authors:  Max Reinshagen; Ekkehard Schütz; Victor W Armstrong; Christoph Behrens; Christian von Tirpitz; Andreas Stallmach; Hans Herfarth; Jürgen Stein; Peter Bias; Guido Adler; Maria Shipkova; Wolfgang Kruis; Michael Oellerich; Nicolas von Ahsen
Journal:  Clin Chem       Date:  2007-05-10       Impact factor: 8.327
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.